Earnings Results
Barinthus Biotherapeutics plc (NASDAQ:BRNS) is scheduled to report its Q3 earnings results on November 06, 2026 after market close.
Analysts expect the Healthcare company to report earnings per share of $-0.26, below the $0.00 reported in the same quarter last year. Revenue is expected to come in at , down from a year ago.
Company Overview
The stock currently trades at $0.74 with a market capitalization of $29.6M.
Ahead of Barinthus Biotherapeutics plc's earnings report, investors are watching several key metrics beyond the headline EPS number. Revenue growth, margin trends, and forward guidance will likely carry more weight than a single quarter's earnings figure in determining the stock's direction after the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Barinthus Biotherapeutics plc should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.
Barinthus Biotherapeutics plc Earnings History
| Quarter | EPS Actual | EPS Est. | Surprise |
| Q2 (Aug 2026) | $-0.26 | $-0.30 | +13.3% |
| Q1 (Apr 2026) | $-0.14 | $-0.30 | +53.3% |
| Q4 (Mar 2026) | $-0.27 | $-0.37 | +27.0% |
Related Tools: Earnings Calendar | View BRNS Stock Page
Frequently Asked Questions
When does Barinthus Biotherapeutics plc report earnings?
Check the latest earnings dates on our BRNS earnings page or the Earnings Calendar.
Did BRNS beat earnings estimates?
See the full Q3 results including EPS actual vs estimate on our BRNS earnings page.